Clinical trial

Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer

NCT05345860

Drugs and interventions used in this trial

6 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

OTHER · Unmapped registry intervention The MRD strategy for high risk or MRD+ TNBC patients Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention The MRD strategy for high risk or MRD+ HER2+ patients Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention The MRD strategy for high risk or MRD+ ER+ patients Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention The MRD strategy for low risk and MRD- TNBC patients Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention The MRD strategy for low risk and MRD- HER2+ patients Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention The MRD strategy for low risk and MRD- ER+ patients Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer

Design: INTERVENTIONAL · Status: RECRUITING · Phase: NA

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2022-03-24

PhaseNA

Conditions

Early-stage Breast Cancerunresolved

Interventions

The MRD strategy for high risk or MRD+ TNBC patientsOTHER

The MRD strategy for high risk or MRD+ HER2+ patientsOTHER

The MRD strategy for high risk or MRD+ ER+ patientsOTHER

The MRD strategy for low risk and MRD- TNBC patientsOTHER

The MRD strategy for low risk and MRD- HER2+ patientsOTHER

The MRD strategy for low risk and MRD- ER+ patientsOTHER

Sponsors & collaborators

Cancer Institute and Hospital, Chinese Academy of Medical Scienceslead sponsor

Beijing Huanxing Cancer Hospitalcollaborator

Chinese Academy of Medical Sciencescollaborator

Mapped research locations

BeijingBeijing Municipality, China2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05345860 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.